Tumour invasion and metastasis: Challenges facing drug discovery

Current Opinion in Pharmacology

Volumn 5, Issue 4 SPEC. ISS., 2005, Pages 374-381

  Elvin, Paul ^a   Garner, Andrew P ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZD 0530; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; DASATINIB; ERLOTINIB; FASUDIL; GEFITINIB; IMATINIB; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY; PHA 665752; SK 1606; TRASTUZUMAB; UNCLASSIFIED DRUG; WF 536; WX UK1;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER INVASION; CLINICAL TRIAL; DRUG RESEARCH; DRUG RESPONSE; DRUG TARGETING; HUMAN; MEDICAL ETHICS; METASTASIS; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT FAILURE;

EID: 21644479899     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2005.02.008     Document Type: Review

References (55)

1. D. Hanahan R.A. Weinberg The hallmarks of cancer Cell 100 2000 57-70
2. P. Friedl K. Wolf Tumour-cell invasion and migration: Diversity and escape mechanisms Nat Rev Cancer 3 2003 362-374
3. J. Condeelis J.E. Segall Intravital imaging of cell movement in tumours Nat Rev Cancer 3 2003 921-930
4. B. Weigelt A.M. Glas L.F. Wessels A.T. Witteveen Peterse JL, van't Veer LJ: Gene expression profiles of primary breast tumors maintained in distant metastases Proc Natl Acad Sci USA 100 2003 15901-15905
5. W. Wang S. Goswami K. Lapidus A.L. Wells J.B. Wyckoff E. Sahai R.H. Singer J.E. Segall J.S. Condeelis Identification and testing of a gene expression signature of invasive carcinoma cells within primary mammary tumors Cancer Res 64 2004 8585-8594
6. A.J. Minn Y. Kang I. Serganova G.P. Gupta D.D. Giri M. Doubrovin V. Ponomarev W.L. Gerald R. Blasberg J. Massague Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors J Clin Invest 115 2005 44-55
7. K. Wolf I. Mazo H. Leung K. Engelke U.H. von Andrian E.I. Deryugina A.Y. Strongin E.B. Brocker P. Friedl Compensation mechanism in tumor cell migration: Mesenchymal-amoeboid transition after blocking of pericellular proteolysis J Cell Biol 160 2003 267-277
8. E. Sahai C.J. Marshall Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis Nat Cell Biol 5 2003 711-719
9. K. Almholt L.R. Lund J. Rygaard B.S. Nielsen K. Dano J. Romer M. Johnsen Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice Int J Cancer 113 2005 525-532
10. N.A. Bhowmick A. Chytil D. Plieth A.E. Gorska N. Dumont S. Shappell M.K. Washington E.G. Neilson H.L. Moses TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia Science 303 2004 848-851
11. A.L. Hopkins C.R. Groom The druggable genome Nat Rev Drug Discov 1 2002 727-730
12. C. Lipinski A. Hopkins Navigating chemical space for biology and medicine Nature 432 2004 855-861
13. L.M. Coussens B. Fingleton L.M. Matrisian Matrix metalloproteinase inhibitors and cancer: Trials and tribulations Science 295 2002 2387-2392
14. I.J. Enyedy S.L. Lee A.H. Kuo R.B. Dickson C.Y. Lin S. Wang Structure-based approach for the discovery of bis-benzamidines as novel inhibitors of matriptase J Med Chem 44 2001 1349-1355
15. A.V. Galkin L. Mullen W.D. Fox J. Brown D. Duncan O. Moreno E.L. Madison D.B. Agus CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts Prostate 61 2004 228-235
16. T.W. Rockway V.L. Giranda Inhibitors of the proteolytic activity of urokinase type plasminogen activator Curr Pharm Des 9 2003 1483-1498
17. T. Steinmetzer Synthetic urokinase inhibitors as potential antitumor drugs IDrugs 6 2003 138-146
18. S. Ertongur S. Lang B. Mack K. Wosikowski B. Muehlenweg O. Gires Inhibition of the invasion capacity of carcinoma cells by WX-UK1, a novel synthetic inhibitor of the urokinase-type plasminogen activator system Int J Cancer 110 2004 815-824
19. M.E. Noble J.A. Endicott L.N. Johnson Protein kinase inhibitors: insights into drug design from structure Science 303 2004 1800-1805
20. Y.P. Lim C.Y. Wong L.L. Ooi B.J. Druker R.J. Epstein Selective tyrosine hyperphosphorylation of cytoskeletal and stress proteins in primary human breast cancers: Implications for adjuvant use of kinase-inhibitory drugs Clin Cancer Res 10 2004 1-7
21. J.M. Golas K. Arndt C. Etienne J. Lucas D. Nardin J. Gibbons P. Frost F. Ye D.H. Boschelli F. Boschelli SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice Cancer Res 63 2003 375-381
22. L.J. Lombardo F.Y. Lee P. Chen D. Norris J.C. Barrish K. Behnia S. Castaneda L.A. Cornelius J. Das A.M. Doweyko et al. Discovery of N-(2-chloro-6-methyl-
23. P.A. Ple T.P. Green L.F. Hennequin J. Curwen M. Fennell J. Allen B.C. LambertVan Der G. Costello Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src J Med Chem 47 2004 871-887
24. Hennequin LF, Allen J, Costello GF, Fennell M, Green TP, Jacobs V, Morgentin R, Olivier A, Ple PA: The discovery of AZD0530: A novel, oral, highly selective and dual-specific inhibitor of the Src and Abl family kinases. 96th Annual Meeting of AACR; 16-20 April 2005; Anaheim CA [Abstract 2537].
25. M. Sattler Y.B. Pride P. Ma J.L. Gramlich S.C. Chu L.A. Quinnan S. Shirazian C. Liang K. Podar J.G. Christensen R. Salgia A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase Cancer Res 63 2003 5462-5469
26. J.G. Christensen R. Schreck J. Burrows P. Kuruganti E. Chan P. Le J. Chen X. Wang L. Ruslim R. Blake et al. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo Cancer Res 63 2003 7345-7355
27. X. Wang P. Le C. Liang J. Chan D. Kiewlich T. Miller D. Harris L. Sun A. Rice S. Vasile et al. Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion Mol Cancer Ther 2 2003 1085-1092
28. Y.W. Zhang Y. Su N. Lanning M. Gustafson N. Shinomiya P. Zhao B. Cao G. Tsarfaty L.M. Wang R. Hay G.F. Vande Woude Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor Oncogene 24 2005 101-106
29. M. Nakajima K. Hayashi Y. Egi K. Katayama Y. Amano M. Uehata M. Ohtsuki A. Fujii K. Oshita H. Kataoka et al. Effect of Wf-536, a novel ROCK inhibitor, against metastasis of B16 melanoma Cancer Chemother Pharmacol 52 2003 319-324
30. M. Nakajima K. Hayashi K. Katayama Y. Amano Y. Egi M. Uehata N. Goto T. Kondo Wf-536 prevents tumor metastasis by inhibiting both tumor motility and angiogenic actions Eur J Pharmacol 459 2003 113-120
31. A.V. Somlyo C. Phelps C. Dipierro M. Eto P. Read M. Barrett J.J. Gibson M.C. Burnitz C. Myers A.P. Somlyo Rho kinase and matrix metalloproteinase inhibitors cooperate to inhibit angiogenesis and growth of human prostate cancer xenotransplants FASEB J 17 2003 223-234
32. S.P. Davies H. Reddy M. Caivano P. Cohen Specificity and mechanism of action of some commonly used protein kinase inhibitors Biochem J 351 2000 95-105
33. M. Harris Monoclonal antibodies as therapeutic agents for cancer Lancet Oncol 5 2004 292-302
34. Y. Tokuda Antibodies as molecular target-based therapy: Trastuzumab Int J Clin Oncol 8 2003 224-229
35. D. Cunningham Y. Humblet S. Siena D. Khayat H. Bleiberg A. Santoro D. Bets M. Mueser A. Harstrick C. Verslype et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 2004 337-345
36. H. Hurwitz L. Fehrenbacher W. Novotny T. Cartwright J. Hainsworth W. Heim J. Berlin A. Baron S. Griffing E. Holmgren et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335-2342
37. M. Kong-Beltran J. Stamos D. Wickramasinghe The Sema domain of Met is necessary for receptor dimerization and activation Cancer Cell 6 2004 75-84
38. D. Kirchhofer X. Yao M. Peek C. Eigenbrot M.T. Lipari K.L. Billeci H.R. Maun P. Moran L. Santell C. Wiesmann R.A. Lazarus Structural and functional basis of the serine protease-like hepatocyte growth factor beta-chain in Met binding and signaling J Biol Chem 279 2004 39915-39924
39. J. Stamos R.A. Lazarus X. Yao D. Kirchhofer C. Wiesmann Crystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptor EMBO J 23 2004 2325-2335
40. N. Jessani M. Humphrey W.H. McDonald S. Niessen K. Masuda B. Gangadharan J.R. Yates III B.M. Mueller B.F. Cravatt Carcinoma and stromal enzyme activity profiles associated with breast tumor growth in vivo Proc Natl Acad Sci USA 101 2004 13756-13761
41. D.C. Swinney Biochemical mechanisms of drug action: What does it take for success? Nat Rev Drug Discov 3 2004 801-808
42. J.I. Johnson S. Decker D. Zaharevitz L.V. Rubinstein J.M. Venditti S. Schepartz S. Kalyandrug M. Christian S. Arbuck M. Hollingshead E.A. Sausville Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials Br J Cancer 84 2001 1424-1431
43. J.J. Killion R. Radinsky I.J. Fidler Orthotopic models are necessary to predict therapy of transplantable tumors in mice Cancer Metastasis Rev 17 1998 279-284
44. R.S. Kerbel What is the optimal rodent model for anti-tumor drug testing? Cancer Metastasis Rev 17 1998 301-304
45. S.F. Winter A.B. Cooper N.M. Greenberg Models of metastatic prostate cancer: A transgenic perspective Prostate Cancer Prostatic Dis 6 2003 204-211
46. D.E. Jenkins Y. Oei Y.S. Hornig S.F. Yu J. Dusich T. Purchio P.R. Contag Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis Clin Exp Metastasis 20 2003 733-744
47. J.B. Wyckoff J.G. Jones J.S. Condeelis J.E. Segall A critical step in metastasis: In vivo analysis of intravasation at the primary tumor Cancer Res 60 2000 2504-2511
48. X. Gao Y. Cui R.M. Levenson L.W. Chung S. Nie In vivo cancer targeting and imaging with semiconductor quantum dots Nat Biotechnol 22 2004 969-976
49. A. Saghatelian N. Jessani A. Joseph M. Humphrey B.F. Cravatt Activity-based probes for the proteomic profiling of metalloproteases Proc Natl Acad Sci USA 101 2004 10000-10005
50. I. Kola J. Landis Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3 2004 711-715
51. M.P. Look W.L. van Putten M.J. Duffy N. Harbeck I.J. Christensen C. Thomssen R. Kates F. Spyratos M. Ferno S. Eppenberger-Castori et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients J Natl Cancer Inst 94 2002 116-128
52. S. Benowitz Biomarker boom slowed by validation concerns J Natl Cancer Inst 96 2004 1356-1357
53. W. Pao V. Miller M. Zakowski J. Doherty K. Politi I. Sarkaria B. Singh R. Heelan V. Rusch L. Fulton et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad Sci USA 101 2004 13306-13311
54. L.L. Chen J.C. Trent E.F. Wu G.N. Fuller L. Ramdas W. Zhang A.K. Raymond V.G. Prieto C.O. Oyedeji K.K. Hunt et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors Cancer Res 64 2004 5913-5919
55. M.E. Gorre M. Mohammed K. Ellwood N. Hsu R. Paquette P.N. Rao C.L. Sawyers Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Science 293 2001 876-880